Astria Therapeutics, Inc.

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 22 BOSTON WHARF ROAD, BOSTON, MA, 02210
Mailing Address 22 BOSTON WHARF ROAD, BOSTON, MA, 02210
Phone 617-349-1971
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2024

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment February 12, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 9, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment January 28, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC

Material Events

8-K Acquisition January 21, 2026
High Impact
  • Astria shareholders have overwhelmingly approved the acquisition by BioCryst Pharmaceuticals.
  • Astria shareholders will receive immediate and substantial cash value for their shares.
View Analysis
8-K Legal Issue December 23, 2025
High Impact
  • Astria Therapeutics is facing shareholder lawsuits alleging false or misleading information regarding its acquisition by BioCryst Pharmaceuticals.
  • The lawsuits claim Astria and its board have not been fully transparent or accurate with merger details, potentially affecting shareholder votes.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.